Citation, DOI & article data
Sarcoidosis is a non-caseating granulomatous multisystem disease with a wide range of clinical and radiographic manifestations.
Individual systemic manifestations are discussed in respective articles:
- pulmonary and mediastinal manifestations
- cardiac manifestations
- musculoskeletal manifestations
- head and neck manifestations
- central nervous system manifestations
- abdominal manifestations
- cutaneous manifestations
The remainder of this article pertains to a general discussion of sarcoidosis.
Sarcoidosis occurs all over the world in all ages and races. Attempts to describe accurate epidemiology are complicated by the use of inconsistent diagnostic criteria and variable (often asymptomatic) 9 disease manifestations.
Still, certain epidemiological patterns are reported in the literature:
- age of onset
- most commonly presents between 2nd through 4th decades of life, although diagnosis in children and elderly also recognized 3
- inconsistent data 6
- there may be a small female predominance among African-Americans 3,6
- the highest incidence in African-Americans (36 to 50 per 100,000) 5 and northern European Caucasians
- incidence among Caucasians has been estimated at 11 to 20 per 100,000 4,5
- the reported incidence is lower in Asian populations
- familial clustering of sarcoidosis has been reported, suggesting either a genetic or environmental component of the disease 3,5,7
- the two largest studies suggest a familial relative risk increase ~4x given a single affected first-degree relative 7
Clinical presentation is variable and diagnosis is usually made on the combination of clinical and radiological features.
- half of the patients are asymptomatic
- the rest develop respiratory (e.g. cough and dyspnea) or skin (e.g. erythema nodosum, lupus pernio, scars, plaques) disease 3
- ocular, lacrimal gland and salivary gland involvement are relatively common
- approximately 5% of patients develop neurosarcoidosis 4
Additionally, patients may have specific syndromic presentations:
- Löfgren syndrome: an uncommon but specific acute presentation of sarcoidosis with a better prognosis
- Heerfordt syndrome: an uncommon variant of sarcoidosis comprising of fever, parotid enlargement, facial palsy, and anterior uveitis
Sarcoidosis is a multisystem disorder of unknown etiology characterized by the formation of inflammatory non-caseating granulomas within affected tissues. Histologically, the lesions characteristically demonstrate an absence of a necrotic component, except in rare cases (so-called "necrotizing sarcoid granulomatosis"). The granulomas may resolve spontaneously or progress to fibrosis.
It is thought to represent a disorder of immune regulation, particularly of cell-mediated immunity 3. Mycobacterium and propionibacterium RNA and DNA have been detected in sarcoidosis lesions, raising the possibility of an infectious trigger 4. Reported familial clustering and co-occurrence in monozygotic twins suggest that genetic susceptibility may also play an important role.
Characteristic (but not pathognomonic) histological features include:
- non-caseating granulomas 5
- epithelioid cells, macrophages, multinucleated giant cells, and CD4+ T cells
- fibroblasts, B lymphocytes, and CD8+ T cells may be present more peripherally
- Schaumann bodies: laminated calcium-containing concretions
- asteroid bodies
- necrosis is atypical and may suggest another etiology 5
Biochemical markers include:
- elevated angiotensin-converting enzyme (ACE)
- 40% false negative
- 10% false positive 3
- hypercalcemia and hypercalciuria
90% of patients have pulmonary involvement (although many are asymptomatic) 8. Since chest x-rays are readily available and have a low radiation burden, the pattern of nodal and parenchymal involvement is typically used to 'stage' sarcoidosis (chest x-ray staging of sarcoidosis) 3.
Treatment and prognosis
Treatment is predominantly performed to protect individual organ function and lessen symptom burden, with wise use of immunosuppressive and corticosteroids, to avoid adverse medication effects 13.
Pulmonary involvement is responsible for the majority of morbidity and mortality in patients with sarcoidosis. The overall mortality rate is approximately 5%, with patients who present insidiously faring worse than those who present with an acute onset 1,3. The likelihood of resolution depends on the stage of disease at presentation 3:
- stage I: 60% resolution within 1-2 years
- stage II: 46%
- stage III: 12%
Complications depend on the systemic pattern of disease involvement. As pulmonary sarcoidosis is by far the most common manifestation, so are thoracic complications. They include 3:
- pulmonary fibrosis (stage IV)
- pulmonary arterial hypertension and cor pulmonale
- aspergillomas, which may be complicated by hemoptysis
History and etymology
Historically, sarcoidosis was also known as Besnier-Boeck-Schaumann disease/syndrome, or various combinations thereof, e.g. Besnier-Boeck disease, Boeck disease, or Schaumann syndrome 10.
Sarcoidosis is derived from the Ancient Greek terms, σαρξ (sarc) meaning flesh, ειδος (eidos) meaning form, and σις (-sis), a suffix meaning a process 10,11.
- 1. Collins J, Stern EJ. Chest radiology, the essentials. Lippincott Williams & Wilkins. (2007) ISBN:0781763142. Read it at Google Books - Find it at Amazon
- 2. Nakatsu M, Hatabu H, Morikawa K et-al. Large coalescent parenchymal nodules in pulmonary sarcoidosis: "sarcoid galaxy" sign. AJR Am J Roentgenol. 2002;178 (6): 1389-93. AJR Am J Roentgenol (full text) - Pubmed citation
- 3. Miller BH, Rosado-de-christenson ML, Mcadams HP et-al. Thoracic sarcoidosis: radiologic-pathologic correlation. Radiographics. 1995;15 (2): 421-37. Radiographics (abstract) - Pubmed citation
- 4. Smith JK, Matheus MG, Castillo M. Imaging manifestations of neurosarcoidosis. AJR Am J Roentgenol. 2004;182 (2): 289-95. AJR Am J Roentgenol (full text) - Pubmed citation
- 5. Ganeshan D, Menias CO, Lubner MG et-al. Sarcoidosis from Head to Toe: What the Radiologist Needs to Know. (2018) Radiographics : a review publication of the Radiological Society of North America, Inc. 38 (4): 1180-1200. doi:10.1148/rg.2018170157 - Pubmed
- 6. Cozier YC. Assessing the worldwide epidemiology of sarcoidosis: challenges and future directions. (2016) The European respiratory journal. 48 (6): 1545-1548. doi:10.1183/13993003.01819-2016 - Pubmed
- 7. Rossides M, Grunewald J, Eklund A et-al. Familial Aggregation and Heritability of Sarcoidosis: A Swedish Nested Case-Control Study. (2018) The European respiratory journal. doi:10.1183/13993003.00385-2018 - Pubmed
- 8. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. (1999) American journal of respiratory and critical care medicine. 160 (2): 736-55. doi:10.1164/ajrccm.160.2.ats4-99 - Pubmed
- 9. Hägerstrand I, Linell F. The prevalence of sarcoidosis in the autopsy material from a Swedish town. (1964) Acta medica Scandinavica. Supplementum. 425: 171-4. Pubmed
- 10. William Alexander Newman Dorland. Dorland's Illustrated Medical Dictionary. (2018) ISBN: 9781416023647
- 11. James Morwood, John Taylor. Pocket Oxford Classical Greek Dictionary. (2002) ISBN: 9780198605126
- 12. Dhakshinamoorthy Ganeshan, Christine O. Menias, Meghan G. Lubner et-al. Sarcoidosis from Head to Toe: What the Radiologist Needs to Know. (2018) RadioGraphics. 38 (4): 1180-1200. doi:10.1148/rg.2018170157 - Pubmed
- 13. Gerke A. Treatment of Sarcoidosis: A Multidisciplinary Approach. Front Immunol. 2020;11:545413. doi:10.3389/fimmu.2020.545413 - Pubmed